Curvebeam Ai Ltd. · ASX:CVB
Curvebeam Ai — Investor Presentation (September 2025)
26 slides from Curvebeam Ai's investor presentation, Sep 29, 2025
Slide 1: CurveBeam AI Investor Deck
CURVEBEAM AI (ASX: CVB) INVESTOR DECK September 2025
Slide 2: Disclaimer
DISCLAIMER Introduction Forward looking statements THIS PRESENTATION IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, The information given in this presentation is given for illustrative purposes only and should not be relied upon as DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM TH
Slide 3: Overview of CurveBeam AI
OVERVIEW OF CURVEBEAM AI Commercialising a New Medical Device in CT Scanning Introducing the HiRise™ : • A cone beam CT scanner that scans a patient’s lower extremity (i.e. hip, knee, ankle, foot) whilst under the patient’s own body weight Brief Overview of HiRise™ • Being able to scan a patient und
Slide 4: Additional Capabilities
DRAFT A D D I T I O N A L C A PA B I L I T I E S Providing greater capabilities than traditional CT device H I R I S E TM P R O V I D E S B O T H : 3D Capabilities The HiRise™ is capable of providing 3D images: WEIGHT BEARING TRADITIONAL CT • In the surgeons' office C T C A PA B I L I T I E S C A PA
Slide 5: Targeting Surgeons Market Opportunity (US)
DRAFT TA R G E T I N G S U R G E O N S MARKET OPPORTUNITY (US) Potential US Addressable Market ~17,000+ potential WHY SURGEON PRACTICES? installations (WBCT scanners only)1 (TAM ~ A$10bn)2 Customers3 • Easy to use at the point of care (PoC) • Saves them time (results within minutes) Hospital Based •
Slide 6: Workflow for Surgeons with HiRise
WORKFLOW FOR SURGEONS WITH HIRISE Improved workflow speaks for itself Workflow for Total Joint Replacement (TJR) incorporating bone quality assessment Surgeon refers Surgeon refers CT Scan sent to patient for Bone BMD sent to Surgery Plan patient for CT surgeon Density imaging surgeon imaging 1 week
Slide 7: Option to Purchase or Finance
OPTION TO PURCHASE OR FINANCE The addition of vendor financing creates an attractive financial model for practices Comparison: Outright Purchase vs. Vendor Financing • Orthopaedic offices are often capital-intensive, which can limit outright Considerations Outright Purchase Model Vendor Financing Op
Slide 8: Market Penetration High Profile Case Study
DRAFT M A R K E T P E N E T R AT I O N HIGH PROFILE CASE STUDY HIRISE™ ALREADY ADOPTED BY LEADING CLINICS PRESIDENT JOE BIDEN GETS WEIGHT BEARING CT SCAN #1 globally recognised specialist orthopaedic hospital in the US “A weight-bearing CT scan has all the benefits of a standard CT scan with the add
Slide 9: Growth Strategy
G R O W T H S T R AT E G Y Worldwide partner and distribution network to target an increase in sales United States (Primary Market) • ~17k potential installation sites in the US alone NORTH AMERICA EUROPE ASIA • Approx. 70% of placements to date have been Operations HQ (Penn.) 8 Distributors Targeti
Slide 10: Enhanced HiRise Validation in Knee/Hip
E N H A N C E D H I R I S E ™ VA L I D AT I O N I N K N E E / H I P What is a robotic cut guide Validation ongoing with multiple suppliers of knee products • CVB is currently working to validate HiRise™ for multiple knee suppliers for non-robotic surgery – 1) Restor3d/Conformis, 2) Medacta Knee Oste
Slide 11: China Strategy
C H I N A S T R AT E G Y CVB has entered into a confidential and non-binding term sheet with a Chinese medical device distributor/ manufacturer (Partner) regarding a potential agreement (Proposal) which involves the following key elements: • Appointment of the Partner for a 10-year term to distribut
Slide 12: Sales & Growth Drivers
SALES & GROWTH DRIVERS Continuing to roll-out HiRise™ devices KEY POTENTIAL GROWTH DRIVERS Vendor Financing Option Market Expansion into ASIA BMD FDA Clearance (discussed next slide) Enhanced HiRise™ Robotic Device Validation Q1 FY 26 • 2 HiRise™ purchase orders to date • Expecting a further 2 order
Slide 13: Opportunity for a SaaS Model
OPPORTUNITY FOR A SAAS MODEL • CurveBeam is developing AI based models which are run on the HiRise™ & other CT scanners (MDCT) • Most advanced is bone mineral density (BMD) to diagnose osteoporosis & aid in presurgical planning for knee and hip replacements Traditional CT Scanners & HiRise™ would •
Slide 14: In Summary: 2 Business Models
IN SUMMARY: 2 BUSINESS MODELS Existing reimbursement codes/coverage targeted to drive both business models 1. HiRise CT Business Model • Stryker sells HiRise™ for US$410,000 (circa A$630,000) Daily patient volume through a USA group surgeon office • CurveBeam AI transfers HiRise™ to Stryker • Target
Slide 15: Corporate Snapshot
DRAFT C O R P O R AT E SNAPSHOT Mkt Cap ~$44 million Cash at bank June 30th 2025 $5 million FY24 Revenue ~$6.5m FY25 Revenue ~$12.1m FY24 Loss from ordinary activities ~$23.1m Substantial Shareholders % FY25 Loss from ordinary activities ~$16.8m Others 35% Firetrail Investments 11.25% Arun Singh (Di
Slide 16: Near Term Targeted Milestones
N E A R T E R M TA R G E T E D M I L E S T O N E S 1 Potential commercial partnership in China H2 CY2025 2 Vendor financing – first draw downs and proposals available H2 CY2025 3 Bone Mineral Density (BMD) CT FDA clearance H1 CY2026 4 Chinese FDA (NMPA) approval for US manufactured HiRise™ H2 CY2026
Slide 17: Under Development: Next Generation SkyRise
UNDER DEVELOPMENT: Next Generation SKYRISE TM (entire body scan) • SkyRise targets scans for dynamic structural detail about spinal alignment, joint orientation and supporting muscles. With future bone density & microstructure measures for better planning • AI will target vertebrae with anatomical l
Slide 18: WBCT Competitors
W B C T C O M P E T I T O R S – M A I N LY L I M I T E D T O H O S P I TA L S PlanMed XFI – WBCT – in development/future competition PlanMed Verity • No known regulatory clearances to date • Available today – FDA, CE, TGA • Space & height limits access in group surgeon settings • Partial foot, Ankle
Slide 19: Capital Raising
CAPITAL RAISING
Slide 20: Capital Raising Summary
C A P I TA L R A I S I N G S U M M A RY Successful capital raising of A$6.5 million, supported by existing and new institutional & sophisticated investors • A single tranche non-underwritten placement to raise A$6.5 million (before costs) (Placement). Placement structure and size • The Company will
Slide 21: Capital Raising Summary
C A P I TA L R A I S I N G S U M M A RY Sources, use of funds and indicative timetable Use of Funds A$m Sources A$m Sales & Marketing $2.8m Cash Balance as at 30 June 2025 $5.0m Research & Development $2.0m Offer proceeds $6.5m Supply Chain $0.4m Total Sources $11.5m General Working Capital includin
Slide 22: International Offer Restrictions
I N T E R N AT I O N A L O F F E R R E S T R I C T I O N S International Offer Restrictions pursuant to and in accordance with exemptions in Subdivision (4) Division 1, Part 13 of the Securities and Futures This document does not constitute an offer of new ordinary shares (“New Shares”) of the Compa
Slide 23: Investment Risks
INVESTMENT RISKS 23 I N V E S T O R P R E S E N T A T I O N
Slide 24: Key Investment Risks
KEY INVESTMENT RISKS Potential Chinese distribution/manufacturing Reimbursement availability Regulatory clearances partner • CVB is continuing to engage with the proposed Chinese Partner, however • The commercial success of the Group’s products and services is critically • While the enhanced HiRise™
Slide 25: Key Investment Risks
KEY INVESTMENT RISKS Protection of IP Additional funding risk Market acceptance • If the Group is unable to protect its IP, its competitors could develop and • The Group may need to raise additional funds in the future to support its • Sales of the Group’s products and services depends on the extent
Slide 26: Key Investment Risks
KEY INVESTMENT RISKS Cybersecurity and data protection risks Taxation matters (post-merger) Patient safety and product liability • Laws relating to data privacy are evolving across all jurisdictions. Data • The merger agreement includes a mechanism pursuant to which a portion • The Group faces produ
Curvebeam Ai — Investor Presentation (September 2025) on 6ix